세계 항응고제 시장 규모는 2023년 412억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장이 2024-2032년간 8.9%의 연평균 성장률(CAGR)로 909억 달러에 달할 것으로 예상하고 있습니다. 혈전성 질환 환자 증가, 좌식 생활 습관, 의료 부문의 개선이 시장을 이끄는 주요 요인 중 하나입니다.
항응고제는 혈전 형성을 방지하고 뇌졸중, 심장마비 등 심각한 증상 발생 가능성을 낮추는 의약품입니다. 혈관을 통과하는 혈액의 흐름에 저항하는 기존 혈전의 치료를 돕고, 혈전이 커지는 것을 방지하여 심각한 합병증의 위험을 줄입니다. 항응고제는 정제, 캡슐 등 경구용과 주사제로 나뉘며 강도와 색상도 다양합니다. 현재 직접 경구용 항응고제(DOAc)는 사용이 간편하고 정기적인 모니터링이 필요하지 않기 때문에 점점 더 많이 처방되고 있습니다.
노인 인구 증가, 인간면역결핍바이러스(HIV), 라임병, 비만, C형 간염, 만성 염증, 심혈관 질환의 전 세계 유병률 증가는 전 세계 시장에 긍정적인 영향을 미치는 주요 요인 중 하나입니다. 또한, 좌식 생활습관과 바쁜 업무 일정으로 인해 폐색전증(PE)과 같은 혈전성 질환의 발병률이 증가하면서 전 세계 심장 관련 질환의 성장을 가속하고 있습니다. 또한 장시간 앉아있는 자세, 흡연, 외상, 혈액 질환, 자가면역 질환은 신체의 여러 부위에서 혈액 응고 위험을 증가시켜 항응고제에 대한 수요를 자극하고 있습니다. 이와는 별도로, 신약 개발 연구 개발(R&D) 활동의 신흥 시장 발전과 인공지능(AI) 및 머신러닝(ML)과 같은 첨단 기술의 통합으로 대량의 데이터를 분석하여 잠재적 약물 후보를 식별하고 신약을 개발할 수 있게 됨에 따라 시장 개척에 박차를 가하고 있습니다. 이에 따라 의료 서비스 제공업체들은 유전자 및 임상 데이터를 기반으로 환자 개개인의 항응고 요법을 맞춤화하는 데 집중하고 있으며, AI는 환자에게 가장 효과적인 항응고제의 용량과 유형을 파악하여 합병증 위험을 줄이고 결과를 개선하는 데 도움을 줄 수 있습니다. 또한, 심혈관 건강에 대한 인식을 높이기 위한 비영리 단체의 적극적인 노력과 심장병과 뇌졸중을 예방하기 위한 각국 정부 및 공중보건 기관과의 파트너십이 확대되면서 세계 시장 성장에 힘을 실어주고 있습니다. 의료 부문의 급속한 성장과 의약품의 가격 및 접근성 향상과 같은 다른 요인들도 시장 성장을 가속하고 있습니다.
The global anticoagulants market size reached US$ 41.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 90.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.9% during 2024-2032. The rising cases of thrombotic disorders, sedentary lifestyles, and the improving healthcare sector represent some of the key factors driving the market.
Anticoagulants are medicines that prevent the formation of blood clots and reduce the chances of developing severe conditions, such as strokes and heart attacks. They assist in treating existing blood clots that resist the flow of blood through vessels and prevent them from getting larger and reducing the risk of serious complications. They are available in different strengths and colors and as oral, such as tablets and capsules, and injectable variants. At present, direct oral anticoagulants (DOAc) are increasingly being prescribed on account of their ease of use and lack of need for routine monitoring.
The growing geriatric population and increasing prevalence of human immunodeficiency virus (HIV), lyme disease, obesity, hepatitis C, chronic inflammation, and cardiovascular disorders across the globe represent one of the key factors positively influencing the market across the globe. In addition, rising cases of thrombotic disorders, such as pulmonary embolism (PE), on account of sedentary lifestyles and hectic work schedules are inducing the growth of heart-related diseases worldwide. Moreover, extended sitting, smoking, trauma, blood disorders, and autoimmune diseases are increasing the risk of blood clotting in different parts of the body, which, in turn, is catalyzing the demand for anticoagulants. Apart from this, increasing advancements in research and development (R&D) activities in drug discovery and the integration of advanced technologies, such as artificial intelligence (AI) and machine learning (ML) to analyze large amounts of data, identify potential drug candidates and develop a new drug is fueling the market growth. In line with this, healthcare providers are focusing on personalizing anticoagulant therapy for individual patients based on their genetic and clinical data. AI assists in identifying the most effective dose and type of anticoagulant for the patient, which, in turn, reduces the risk of complications and improves outcomes. Furthermore, favorable initiatives by non-profitable organizations to promote awareness about cardiovascular health and the growing partnerships between governments of various countries and public health agencies to prevent heart disease and strokes are propelling the growth of the market worldwide. Other factors like the burgeoning healthcare sector and increasing affordability and accessibility of drugs are stimulating the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anticoagulants market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration, distribution channel and application.
Novel Oral Anticoagulants (NOACs)
Heparin and Low Molecular Weight Heparin (LMWH)
Vitamin K Antagonist
Others
The report has provided a detailed breakup and analysis of the anticoagulants market based on the drug class. This includes novel oral anticoagulants (NOACs), heparin and low molecular weight heparin (LMWH), vitamin K antagonist, and others. According to the report, novel oral anticoagulants (NOACs) represented the largest segment.
Oral Anticoagulant
Injectable Anticoagulant
A detailed breakup and analysis of the anticoagulants market based on the route of administration has also been provided in the report. This includes oral anticoagulant and injectable anticoagulant. According to the report, oral anticoagulant accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Stores
Others
A detailed breakup and analysis of the anticoagulants market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, online stores, and others. According to the report, hospital pharmacies accounted for the largest market share.
Atrial Fibrillation and Heart Attack
Stroke
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Others
A detailed breakup and analysis of the anticoagulants market based on the application has also been provided in the report. This includes atrial fibrillation and heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. According to the report, atrial fibrillation and heart attack accounted for the largest market share.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for anticoagulants. Some of the factors driving the North America anticoagulants market included the increasing prevalence of thrombotic disorders, developed healthcare sector, ongoing research and development (R&D) activities in drug discovery etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global anticoagulants market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc, Aspen Holdings, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc., Sanofi, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.